Review Topical Sections

Salmon calcitonin: conformational changes and stabilizer effects

  • Received: 03 October 2015 Accepted: 09 November 2015 Published: 11 November 2015
  • The therapeutic activity of peptides or protein drugs is highly dependent on their conformational structure. The protein structure is flexible and responds to external conditions, which may compromise the protein's native conformation and influence its physical and chemical stability. The physical and chemical stability of peptides or protein drugs are important characteristics of biopharmaceutical products. Calcitonin (CT) is a polypeptide hormone that participates in diverse physiological functions in humans; therefore, it is a potentially useful protein for investigations of different aspects of pharmacology and drug delivery systems. Of the different types of CT available for clinical use, salmon CT (sCT) is one of the most potent. In this review article, the commercially available sCT was selected as a suitable peptide candidate for the discussion of its stability and conformational changes in the aqueous and solid states using Fourier transform infrared (FTIR) spectroscopic analysis under different external conditions, including pH, temperature, drying method, and added excipients. Particularly, excipients that have been optimized as stabilizers of sCT in aqueous solution and as lyophilized and spray-dried drug formulations are also discussed.

    Citation: Shan-Yang Lin. Salmon calcitonin: conformational changes and stabilizer effects[J]. AIMS Biophysics, 2015, 2(4): 695-723. doi: 10.3934/biophy.2015.4.695

    Related Papers:

    [1] Amira Bouhali, Walid Ben Aribi, Slimane Ben Miled, Amira Kebir . Impact of immunity loss on the optimal vaccination strategy for an age-structured epidemiological model. Mathematical Biosciences and Engineering, 2024, 21(6): 6372-6392. doi: 10.3934/mbe.2024278
    [2] Holly Gaff, Elsa Schaefer . Optimal control applied to vaccination and treatment strategies for various epidemiological models. Mathematical Biosciences and Engineering, 2009, 6(3): 469-492. doi: 10.3934/mbe.2009.6.469
    [3] Haoyu Wang, Xihe Qiu, Jinghan Yang, Qiong Li, Xiaoyu Tan, Jingjing Huang . Neural-SEIR: A flexible data-driven framework for precise prediction of epidemic disease. Mathematical Biosciences and Engineering, 2023, 20(9): 16807-16823. doi: 10.3934/mbe.2023749
    [4] Markus Thäter, Kurt Chudej, Hans Josef Pesch . Optimal vaccination strategies for an SEIR model of infectious diseases with logistic growth. Mathematical Biosciences and Engineering, 2018, 15(2): 485-505. doi: 10.3934/mbe.2018022
    [5] Rongjian Lv, Hua Li, Qiubai Sun, Bowen Li . Model of strategy control for delayed panic spread in emergencies. Mathematical Biosciences and Engineering, 2024, 21(1): 75-95. doi: 10.3934/mbe.2024004
    [6] Sarafa A. Iyaniwura, Musa Rabiu, Jummy F. David, Jude D. Kong . Assessing the impact of adherence to Non-pharmaceutical interventions and indirect transmission on the dynamics of COVID-19: a mathematical modelling study. Mathematical Biosciences and Engineering, 2021, 18(6): 8905-8932. doi: 10.3934/mbe.2021439
    [7] Jerzy Klamka, Helmut Maurer, Andrzej Swierniak . Local controllability and optimal control for\newline a model of combined anticancer therapy with control delays. Mathematical Biosciences and Engineering, 2017, 14(1): 195-216. doi: 10.3934/mbe.2017013
    [8] Bruno Buonomo . A simple analysis of vaccination strategies for rubella. Mathematical Biosciences and Engineering, 2011, 8(3): 677-687. doi: 10.3934/mbe.2011.8.677
    [9] M. H. A. Biswas, L. T. Paiva, MdR de Pinho . A SEIR model for control of infectious diseases with constraints. Mathematical Biosciences and Engineering, 2014, 11(4): 761-784. doi: 10.3934/mbe.2014.11.761
    [10] Pannathon Kreabkhontho, Watchara Teparos, Thitiya Theparod . Potential for eliminating COVID-19 in Thailand through third-dose vaccination: A modeling approach. Mathematical Biosciences and Engineering, 2024, 21(8): 6807-6828. doi: 10.3934/mbe.2024298
  • The therapeutic activity of peptides or protein drugs is highly dependent on their conformational structure. The protein structure is flexible and responds to external conditions, which may compromise the protein's native conformation and influence its physical and chemical stability. The physical and chemical stability of peptides or protein drugs are important characteristics of biopharmaceutical products. Calcitonin (CT) is a polypeptide hormone that participates in diverse physiological functions in humans; therefore, it is a potentially useful protein for investigations of different aspects of pharmacology and drug delivery systems. Of the different types of CT available for clinical use, salmon CT (sCT) is one of the most potent. In this review article, the commercially available sCT was selected as a suitable peptide candidate for the discussion of its stability and conformational changes in the aqueous and solid states using Fourier transform infrared (FTIR) spectroscopic analysis under different external conditions, including pH, temperature, drying method, and added excipients. Particularly, excipients that have been optimized as stabilizers of sCT in aqueous solution and as lyophilized and spray-dried drug formulations are also discussed.


    1. Introduction

    Since the publication of the seminal paper [11] mathematical compartmental models are widely used to describe infectious diseases dymanics in large populations (see, for example [9], [4], [2] and [8]). It is well accepted that once an infected individual comes into contact with an unaffected population, the disease will spread by contact with the infectious individuals. Compartmental models divide the population into compartments characterizing the spread of the diseases and letters are used to denote the number of individuals in each compartment. Usually, the size of the population to be studied is $N$, $S$ is the number of susceptible individuals and the number of infectious individuals is $I$. The letter $R$ is also used to denote the number of those who recover from the disease or, as in [11], those who are removed from the disease by death or by recovery. The nature of the disease as well the reason why the models are studied may dictate the need for different compartments to be included. For example, SEIR models are used for diseases where infected individuals do not become immediately infectious; they are considered to be exposed to the disease and placed in compartment $E$, being moved to the $I$ compartment only after some latent period of time.

    The basic reproduction number, $R_0$, measures the transmission potential of a disease (see, for example, [10]). It is defined as "the expected number of secondary cases produced by a single (typical) infection in a completely susceptible population". From the mathematical point of view, it is an important concept when dealing with the dynamic systems defined by the compartmental models (SIR model, SEIR models, etc) because of its relevance to the stability of the equilibrium points. Indeed, there is a vast literature devoted to the stability analysis of such models; in this respect we refer the reader to [4] [2] and [8] (to name but a few!) and references within. Recently one has witnessed an increasing interest on applications of optimal control to such models (see [17], [13], [18], [1], [12], [6] and [16]). This comes as no surprise since optimal control theory has been a successful tool in the design of different control strategies for dynamic systems in general ([20]).

    Many papers on optimal control applied to epidemiology propose $L^2$ costs (see, for example, [17] and [1]). One reason for this is that a closed form of the optimal control may be obtained, a form that facilitates the numerical verification of the solution (although, by itself, it does not guarantees that the solution is the optimal one since it usually depends on the multipliers). On the other hand, it has been argued that $L^1$ costs are appropriated to biological systems while those with $L^2$ costs are not ([13]). This reasoning may explain the attention optimal control problems with $L^1$ costs have recently gained; see, for example, [13], [12] and [16].

    In this paper we focus on optimal control problems to control, via vaccination, the spread of a disease described by a SEIR model. We follow closely the approach in [16]: we consider $L^1$ costs, we solve the problems numerically applying the direct method, we use known software packages, and we present numerical solutions that satisfy necessary optimality conditions with high accuracy. Notably, and differing from [16], we work with a normalized SEIR model.

    The normalized SEIR model differs from the usual SEIR model since the variables are fractions of the whole population instead of the number of individuals in each compartment. The theoretical and numerical treatment involving the latter model is usually done as if the variables are continuous and not integers; treating such variables as integers would demand the use of integer programming what is known to be very heavy computationally. When we turn to normalized models the variables are, by nature, continuous. In the literature, normalized models are common when the total population is assumed to remain constant during the time frame under study. This is not our case; here we normalize a SEIR model that incorporates exponential natural birth and death, as well as disease-caused death (similarly to what is done in [14]). As far as optimal control is concerned, normalizing such model brings out some new issues related to the choice of costs and the introduction of non standard constraints, questions we discuss here when comparing optimal control for normalized and not normalized SEIR models.

    Herein, we refer to the SEIR model, where the variables $S$, $E$, $I$ and $R$ denote the number of individuals in each compartment, as the classical SEIR model as opposed to the normalized SEIR model.

    We emphasize that we do not concentrate on any particular disease. Rather, our aim is to illustrate how previously proposed optimal control formulations can be handled by this new model, when different scenarios are considered. Taking into account that the set of parameters for the population in [16], based on [17], are not to be found in today's world, we use different population's parameters closed related to some European countries.

    Like other models in epidemiology, SEIR models represent only a rough approximation of reality. However, they provide new insights into the spreading of diseases and, when optimal control is applied, new insight on different vaccination policies.

    This paper is organized in the following way. In Section 2 we introduce an optimal control problem with $L^1$ cost involving the classical SEIR model and its "normalized" counterpart. A brief description of our numerical methods as well as the tables with the set of parameters used in our simulation are presented in Section 3. Numerical methods give a helping hand for the discussion on the pros and cons of optimal control problems with classical and normalized models presented in Section 4. This discussion highlights the need for a criterious choice of cost. In Sections 5 and 6, we solve our optimal control problem numerically partially validating our solution using the maximum principle and the computed multipliers. Conclusions follow in the last section of this paper.


    2. Optimal control problems for SEIR models with $L^1$ cost

    The SEIR model is a compartmental model well accepted as modelling some infectious diseases. At each instant $t$, $S(t)$, $E(t)$, $I(t)$, and $R(t)$ denote the number of individuals in the susceptible, exposed, infectious and recovered compartments. The total population is $N(t) = S(t) + E(t) + I(t) + R(t)$. We assume that our population has exponential natural birth rate $b$ and death rate $d$ and that that all newborns are susceptible to the diseases. The disease transmission is described by the parameters $f$, denoting the rate at which the exposed individuals become infectious, $g$, denoting the rate at which infectious individuals recover, $a$, denoting the death rate due to the disease and $c$, denoting the disease incidence coefficient of horizontal transmission (vertical transmission is not considered). The rate of transmission of the disease is $c\frac{I(t)}{N(t)}$. For simplicity the parameters $a$, $b$, $c$, $d$ and $f$ are assumed to be constants. For more information about such model we refer the reader to [2], [10], [17] and references within.

    Optimal control techniques for SEIR models allow the study of different vaccines policies; different policies are confronted in [17] and [1] where the minimizing cost is $L^2$, and in [16], covering the case of $L^1$ cost. As in the aforementioned works we assume that only susceptible people is vaccinated (implying that it is possible to distinguish between exposed and susceptible individuals) and that the vaccine is effective so that all vaccinated susceptible individuals become immune. Let $u(t)$ represent the percentage of the susceptible individuals being vaccinated per unit of time. Taking all the above considerations into account we are led to the following dynamical system (see [17]):

    $ ˙S(t)=bN(t)dS(t)cS(t)I(t)N(t)u(t)S(t),S(0)=S0,
    $
    (1)
    $ ˙E(t)=cS(t)I(t)N(t)(f+d)E(t),E(0)=E0,
    $
    (2)
    $ ˙I(t)=fE(t)(g+a+d)I(t),I(0)=I0,
    $
    (3)
    $ ˙N(t)=(bd)N(t)aI(t),N(0)=N0,
    $
    (4)

    where $S_0$, $E_0$, $I_0$ and $N_0$ are nonnegative initial conditions.

    For some $\bar u\geq 0$, we impose the following control constraint to $u$:

    $ \label{control-constraint} 0 \leq u(t) \leq \bar u \;\;\;\; a.e. \; t \in [0,T] , $ (5)

    where $T$ represents the period of time under consideration. The recovered population is related to the total population by $N(t) = S(t) + E(t) + I(t) + R(t)$. Hence, $R(t) = N(t) -S(t) - E(t) - I(t)$ which gives the differential equation

    $ \label{Rdifeq} \dot R(t) = g I(t)-dR(t)+u(t)S(t) , \;\;\;\; R(0) = R_0 . $ (6)

    Here, the aim of applying optimal control to SEIR models is to control the spreading of the disease with some minimum financial cost. The cost should then be a weighted sum of the society financial costs of having, at each time, $I(t)$ infected individuals and the cost of the vaccination effort what is mathematical translated as (7). This leads to the $L^1$ cost as in [16]:

    $ \label{L1-objective} J_C(X,u)= \int_0^{T} \left( AI(t)+Bu(t)\right)~dt, $ (7)

    where $X=(S,E,I,N)$ and $A>0$, $B>0$ are weight parameters related with financial costs.

    Throughout this paper we refer to the optimal control problem of minimizing $J_1(X,u)$ over all $X \in W^{1,1}([0,T]:\mathbb{R}^4)$ and all piecewise continuous functions $u:[0,T]\to \mathbb{R}$ satisfying (1)-(6) and (5) as the classical and basic optimal control problem:

    $\nonumber (P) \left\{ MinimizeT0(AI(t)+Bu(t)) dtsubject to˙S(t)=bN(t)dS(t)cS(t)I(t)N(t)u(t)S(t),S(0)=S0,˙E(t)=cS(t)I(t)N(t)(f+d)E(t),E(0)=E0,˙I(t)=fE(t)(g+a+d)I(t),I(0)=I0,˙N(t)=(bd)N(t)aI(t),N(0)=N0,u(t)[0,ˉu] for a. e.t[0,T], with ˉu]0,1].
    \right. \nonumber $

    Next, we associate $(P)$ with a normalized optimal control problem. Normalizing models are obtained considering the percentage of the total population to be $1$ at each instant $t$. Then, defining

    $ s(t)=\frac{S(t)}{N(t)}, \;\;\;\; e(t)=\frac{E(t)}{N(t)},\;\;\;\; i(t)=\frac{I(t)}{N(t)}, \;\;\;\; r(t)=\frac{R(t)}{N(t)} , $ (8)

    we have

    $ s(t)+e(t)+i(t)+r(t)=1\text{ for all }t. $ (9)

    Notice that $s(t)$ is the percentage of the population in compartment $S(t)$, $e(t)$ is the percentage of the population in compartment $E(t)$, $i(t)$ is the percentage of the population in compartment $I(t)$ and $r(t)$ be the percentage of the population in compartment $R(t)$. The normalized counterpart of (1)-(6) is then:

    $ ˙s(t)=bcs(t)i(t)bs(t)+ai(t)s(t)u(t)s(t),
    $
    (10)
    $ ˙e(t)=cs(t)i(t)(f+b)e(t)+ai(t)e(t),
    $
    (11)
    $ ˙i(t)=fe(t)(g+a+b)i(t)+ai2(t),
    $
    (12)
    $ ˙r(t)=gi(t)rb(t)+ai(t)r(t)+u(t)s(t).
    $
    (13)

    Remarkably, the dead rate parameters do not appear in this model (a feature we discuss in Remark 1 below). It is a simple matter to see that due to (9) we can discard equation (13), allowing us to reduce the number of differential equations from the normalized SEIR model (10)-(13).

    Now we are faced with the choice of the cost for the normalized model. Taking into account that the main aim is to control or to eliminate the disease from the population under study, different costs is may be considered, reflecting different concerns.

    The choice of the cost for $(P)$ is based on the need to define vaccine policies to minimize some social and financial burden of the disease into the population. The cost $J_C$ for $(P)$ captures two easily recognized social and financial costs that the infectious disease imposes on a society; the burden of having people infected among the population, translated in $J_C$ as $AI(t)$, and the burden of vaccination to combat the spreading of the diseases, translated in $J_C$ as $Bu(t)$. Noteworthy, the weights $A$ and $B$ can be easily changed to reflect different scenarios.

    An almost straightforward translation of this reasoning to our normalized model yields $J_n(x,u)=\displaystyle\int_0^T (\rho i(t)+u(t))~dt,$ where $x=(s,e,i)$ is now the state variable and $\rho$ a parameter reflecting different weights on $i$ and $u$. Numerically speaking, this cost is clearly different to $J_C$ since its two terms are now both percentages while $J_C$ has a weighted sum of two distinctive amounts. Not surprising, some simple tuning of $\rho$ may lead to similar results specially in situations where the total population $N$ does not vary much and, in particular, when the total population remains constant. However, $J_n$ demands that the cost of infected people should be calculated in terms of the percentage of people infected instead of using the number of infected people as in $J_C$, something that depends on the economic practices.

    We postpone this discussion of the introduction of different costs to future research and we proceed now with the cost $J_n$ above for our normalized model. Putting all together we are led to the normalized basic optimal control problem:

    $\nonumber (P_{n}) \left\{ MinimizeT0(ρi(t)+u(t)) dtsubject to˙s(t)=bcs(t)i(t)bs(t)+ai(t)s(t)u(t)s(t),s(0)=s0,˙e(t)=cs(t)i(t)(f+b)e(t)+ai(t)e(t),e(0)=e0,˙i(t)=fe(t)(g+a+b)i(t)+ai2(t),i(0)=i0,u(t)[0,ˉu] for a. e.t[0,T], with ˉu]0,1].
    \right. \nonumber $

    Note that the dynamics is of the form $\dot{x}(t)=f(x(t))+g(x(t))u$, with $x=(s,\;e,\;i)$ and appropriate functions $f(x)$ and $g(x)$.

    Remark 1. A word of caution regarding the way the system (10)-(13) is viewed. We cannot interpret the dynamics between these new compartments in the same way as with the classical model. Indeed, in equation (10) the term $+ai(t)s(t)$ does not mean that those who died of the disease become susceptible as if reborn in a different compartment. Instead, this dynamical model can be better understood using fluid analogies in the following way. Consider a system with four tanks with the same amount of water circulating between them. At each instant $t$ the total amount of water in the system is constant but the level of water in each tank varies. This analogy is presented in Figure 1 assuming that $u(t)=0$. As mentioned before, $(P_n)$ does not depend on the parameter $d$. This happens because the normal dead rate is equal for any compartment and thus it does not affect the distribution of population into compartments. On the other hand, the birth rate works as if feeding the susceptible compartment.

    Figure 1. Fluid Analogy of the Normalized SEIR compartmental model.

    We will discuss pros and cons of $(P)$ and $(P_n)$ using numerical solutions. Before that, however, we need to briefly present some remarks on the numerical tools and to describe the set of parameters used in our simulations.


    3. Numerical methods and data for simulations

    Optimal control problems can be solved numerically by direct or indirect methods. Here, we opt to use the direct method (for a description these two methods see, for example, [19]): first the problem is discretized and the subsequent optimization problem is then solved using software packages with large scale nonlinear continuous optimization solvers. In this work all the simulations were made with the Applied Modelling Programming Language (AMPL), developed by [7], and interfaced to the Interior-Point optimization solver IPOPT, developed by [21]. Alternatively, the optimization solver WORHP (see [3]) can also be interfaced with AMPL. We refer the reader to [16] and references within for more information on software for optimal control problems.

    The application of the Maximum Principle to problems in the form of $(P)$ (the control appearing linearly in the dynamics and the cost and with box control constraints) yields that the solution is a concatenation of bang-bang arcs and$/$or singular arcs. That is the case of $(P_n)$ and $(P)$. When the optimal control is bang-bang, sufficient second order optimality conditions (SSC) can be checked numerically; SSC as described in [15] and [19] can be checked with high accuracy using the control package NUDOCCCS. Alternatively they can also be tested with AMPL interfaced with IPOPTS or with WORHP.

    In all the computations we consider the time horizon to be 20 years: thus $T=20$. The parameters characterizing the population and the disease are in table 1. These parameters do not correspond to any specific population or diseases. In fact, $f$, $a$ and $g$ are equal to those in [17], while $c$ is adapted from the corresponding values in [17]. As for $b$ and $d$, these are closely related to birth rates and death rate in European countries. The disease parameters correspond to a devastating disease as one can see either by calculating the reproduction number, which is higher than 1 (see [10]) or by solving the classical SEIR system ((1)-(6)) with $u(t)=0$. In the next section, and when convenient, we use different parameters but this will be clearly stated. The values of the initial conditions follow those in [17]: for classical SEIR models they are presented at table 2 together with the parameters $A$ and $B$ of the objective functional. The initial conditions for the normalized problem $(P_n)$ are presented at table 3.

    Table 1. Parameters for SEIR models.
    Parameter Description Value
    b Natural birth rate 0.01
    d Death rate 0.0099
    c Incidence coefficient 1.1
    f Exposed to infectious rate 0.5
    g Recovery rate 0.1
    a Disease induced death rate 0.2
    T Number of years 20
     | Show Table
    DownLoad: CSV
    Table 2. Initial Conditions and cost parameters for problems with classical SEIR model.
    Parameter Description Value
    A weight parameter 1
    B weight parameter 2
    S0 Initial susceptible population 1000
    E0 Initial exposed population 100
    I0 Initial infected population 50
    R0 Initial recovered population 15
    N0 Initial population 1165
     | Show Table
    DownLoad: CSV
    Table 3. Initial Conditions and cost parameters for problems with classical SEIR model normalized model.
    Parameter Description Value
    s0 Percentage of initial susceptible population 0.858
    e0 Percentage of initial exposed population 0.086
    i0 Percentage of initial infected population 0.043
     | Show Table
    DownLoad: CSV

    4. Comparison $(P)$ with $(P_n)$

    The problem $(P)$ is sensitive to the dimension of the population. For example, the solution changes when we merely perturb the dead rate parameter, $d$, or when the initial values $S_0$, $E_0$, $I_0$ and $R_0$ are multiplied by a given positive constant. The first situation is illustrated in the left graph of Figure 2, where the optimal control for a problem $(P)$ with $d=0.0099$ is shown together with the optimal control for a problems with $d=0.0005$; although the profile of the optimal control is the same, the switching times do change. Sensitivity of $(P)$ to different initial values is illustrated in the right graph of Figure 2. For a smaller population the optimal control is of the bang-singular-bang type whereas, for a larger population it is bang-bang. In both cases, the percentages of susceptible, exposed and infected initial individuals is the same. Clearly, the cost is in the core of sensitivity of $(P)$ with respect to the size of the initial population and also with respect to different death rates.

    Figure 2. Optimal control for $(P)$: parameters in tables 1 and 2. Left: Optimal control different dead rates: in red for $d=0.0099$ and in blue for $d=0.0005$. Right: Optimal control with different initial values. In red for $S_0$, $E_0$, $I_0$ and $R_0$ as in the table 2 in blue for initial conditions $S_0\times 100$, $E_0\times 100$, $I_0\times 100$ and $R_0\times 100$.

    Although the two problem $(P)$ and $(P_n)$ are different, we can get $(P_n)$ to produce approximately the same solutions of $(P)$ as mentioned above. To do so, we need to choose the parameter $\rho$ in $J_n$ to be $\rho=\dfrac{A\times \pi}{B}$, where $A$ and $B$ are the weights of $I(t)$ and $u(t)$ and $\pi$ is an average of the total population during $T$. An example is shown in 3. Observe that if the total population remains almost constant, we can choose $\pi=N_0$.

    Figure 3. Optimal control for $(P_n)$ with $\rho=500$ in blue. Optimal control calculated for $(P)$ in blue. The parameters are described in tables 1, 3, and 2.

    Clearly, the reason why $(P)$ and the $(P_n)$, with parameters associated to $(P)$, differ resides on the cost. As mentioned before, the cost of $J_n$, introduced in section 2 as an adaptation of $J_C$, requires a fresh approach. Indeed, $(P_n)$ demands that the "financial" cost be expressed in terms of percentages and not numbers of individuals.

    When considering problem $(P_n)$, we are mainly concerned on how the total population is distributed into compartments. Because of the nature of the percentages we use, both the total number of the population as well as the dead rate are simply not there. The problem $(P_n)$ may be useful to simulate the same disease acting on different sized populations but with similar birth rates. Observe also, that if needed, when solving $(P_n)$ numerically we can keep track of the changes of the total the population by adding the differential equation $\dot{N}(t)=(b-d)N(t)-ai(t)N(t)$ to our code. This does not cause any change on the optimal control since the solution does not depend on $N$. While $(P_n)$ has the advantage of covering different populations in one go, it does not always subsumes or replaces $(P)$. For example, the situation when one seeks vaccination policies when the total number of vaccines available are bounded (as in [17]) is tailored for the classical model $(P)$. Mixed constraints like those introduced in [1], i.e., of the form

    $ u(t)S(t)\leq V_0, \label{eq:restricao} $ (14)

    can be mathematically translated to normalized models but they loose their meaning. However, this drawback may be overcome by considering $u(t)\in [0,\bar{u}]$, for a suitable contant $\bar{u}<1$. This technique was also used in [16], for $(P)$, as numerical simulations shows that the results obtained by using this strategy are similar to the solutions obtained by using the restriction described in (14).


    5. Solution of $(P_n)$

    We now focus on the Maximum Principle for the problem $(P_n)$. The Hamiltonian given by

    $H(x,\;p,\;u)=pf(x)+pg(x)u-\lambda(\rho i+u),$

    for appropriated $f$ and $g$, $x=(s,e,i)$ and where $p(t)= \left(p_s(t),p_e(t), p_i(t)\right) \in \mathbb{R}^3$ denotes the adjoint variable. Let $(x^*,u^*) \in W^{1,\infty}\times L^\infty$ be an optimal solution to $(P_n)$. Then the maximum principle [5] asserts the existence of a scalar $\lambda\geq 0$ and an absolutely continuous function $p$ such that the following conditions are satisfied almost everywhere:

    (ⅰ) $\max \{|p(t)|:t\in[0,T]\}+\lambda>0$ (nontriviality condition)

    (ⅱ) $\dot{p}(t)=-H_x[t]=\langle p(t),f_x[t]+g_x[t]u^*(t)\rangle -\lambda (0,\;0, \;\rho)$ (adjoint condition),

    (ⅲ) $H(x^*(t),p(t),u^*(t))=\displaystyle\max_u \{H(x^*(t),p(t),u(t))\::\: 0\leq u \leq \bar{u}\}$ (maximization of the Hamiltonian),

    (ⅳ) $p(T)=0$ (transversality condition).

    Since $(P_n)$ does not have final time constraints on the states, it is well known that the above conditions hold with $\lambda=1$. Set $\phi (t)=H_u[t]=\langle p(t), g[t]\rangle -1$. This is called the switching function and it is of help to deduce a characterization of the optimal control $u^*$ from (ⅰ)-(ⅳ) which we proceed to do next.

    It is a simple matter to see that condition (ⅲ) is equivalent to

    $ \phi (t)u^*(t)=\displaystyle\max\limits_u \{\phi (t)u(t)\::\: 0\leq u \leq \bar{u}\}. $ (15)

    It follows that $u^*$ is bang-bang in an interval $I\subset [0, T]$, if the switching function $\phi$ has a finite number of isolated zeros at which the control switches between $0$ and $\bar u$. If $\phi$ is zero on an interval, then $u^*$ is singular, i.e.,

    $ u^*(t)= \left\{ ˉu, if ϕ(t)>0,0, if ϕ(t)<0,singular, if ϕ(t)=0.
    \right. \label{eq:sis_sing_sem_restr} $
    (16)

    In terms of the data of $(P_n)$ the adjoint condition (ⅱ) reads

    $ -\dot{p}_s(t)\;\;\;\; = (ai(t)-ci(t)-b-u(t))p_s(t)+ci(t)p_e(t), $ (17)
    $ -\dot{p}_e(t) \;\;\;\;= (ai(t)-b-f)p_e(t)+fp_i(t), $ (18)
    $ -\dot{p}_i(t) \;\;\;\; = (as(t)-cs(t))p_s(t)+(cs(t)+ae(t))p_e(t)+\nonumber \\ \;\;\;\;\;\;\;\;\;\;\;\;\;\;\;\;\;\;\;\;\;\;\;\;(2ai(t)-a-b-g)p_i(t)-\rho. $ (19)

    Also, we have

    $ \phi(t)=-1-p_s(t)s(t). $ (20)

    Since our computations show that a singular arc appear, let us assume that $\phi(t)=0$ for $t$ in an interval $I\subset [0,T]$ and check if we can obtain formulas for the singular controls. We work in the region1

    1Since the initial condition belong to the interior of $\mathcal{R}$ and $\bar u\in ]0,1]$, this statement is easily verified numerically.

    ${ \mathcal{R}}:=\left\{(s,e,i)\in\mathbb{R}^3:~s\geq 0,~e\geq 0, ~ i\geq 0\right\}$

    and so we deduce that

    $\phi(t)=0 \text{ implies that }p_s(t) = -\frac{1}{s(t)}< 0.$

    In the interior of the singular interval we have $\dfrac{d \phi}{dt}=0$ and $\dfrac{d^2 \phi}{dt}=0$. Now

    $\dfrac{d\phi}{dt}=cs(t)i(t)p_e(t)-bp_s(t)=0$

    implies that that $p_e = \frac{-b}{cs^2(t)i(t)} \leq 0$. Since

    $ d2ϕdt=aci(t)2pe(t)s(t)aci(t)pe(t)s(t)bci(t)pe(t)s(t)+cfe(t)pe(t)s(t)cgi(t)pe(t)s(t)c2i(t)2pe(t)s(t)ci(t)pe(t)s(t)u(t)+2bci(t)pe(t)+cfi(t)pe(t)s(t)cfi(t)s(t)pi(t)+abi(t)ps(t)bci(t)ps(t)b2ps(t)bps(t)u(t),
    $
    (21)

    depends on the control variable $u$, we say that the singular control (if it exists) is of order one. Moreover, since $p_s(t) \leq 0$ and $p_e(t) \leq 0$, we have

    $\dfrac{d }{d u}\left(\dfrac{d^2 \phi}{d t}\right)=-ci(t)p_e(t)s(t)-bp_s(t)>0.$

    Thus the strict Generalized Legendre-Clebsch Condition (GLC) holds and we can solve $\dfrac{d^2 \phi}{d t}=0$ with respect to the control variable to get

    $ using(x,p)=c(c+a)s(t)i(t)2pe(t)ci(t)pe(t)s(t)+bps(t)+cefs(t)pe(t)b2ps(t)ci(t)pe(t)s(t)+bps(t)+((((ab+fg)s(t)+2b)pe(t)fs(t)pi(t)bps(t))c+abps(t))i(t)ci(t)pe(t)s(t)+bps(t)
    $
    (22)

    It is important to observe that the above expression for singular controls depends on the multipliers. Since we do not establish that the multipliers are unique, we can only expect to use (22) to validate numerical findings but not to prove to optimality. In fact, to prove optimality of computed solution we need to check numerically sufficient conditions. Unfortunately, there are no numerically verifiable sufficient conditions for problems with singular arcs.


    6. Numerical solutions for $(P_n)$

    We now present and discuss the results of our simulations for $(P_n)$. Recall that we use the data in table 1 and 3. We treat three different cases:

    Case 1: $\bar u=1$ and $\rho=500$,

    Case 2: $\bar u=1$ and $\rho=10$,

    Case 3: $\bar u=0.2$ and $\rho=500$.

    In the first two cases the computed optimal control exhibits a bang-singular-bang structure while in the last one the optimal control is bang-bang. For all the three cases we present graphs with the computed controls and trajectories. As in [16] and to keep the exposition short, we do not present the graphs of the multipliers but we give their computed initial values, and we also present the final states, the costs and the switching times

    Case 1. Taking $\bar u$ to be $1$ depicts the situation when all the susceptible population can be vaccinated. The results of the simulations are shown in figures 4 and 5. In Fig. 4 we show that the numeric optimal control and switching function, $\phi$, satisfy (16) while the computed singular control (22) coincides with the computed optimal control $u^*$. The optimal trajectories are presented in Fig. 5.

    Figure 4. Case 1: Computed optimal control $u^*$ plotted together with the singular control computed according to (22) and with the switching function $\phi$. During the first five years $\phi(t)>1$ and during the last eight years $\phi(t)<0$.
    Figure 5. Case 1: optimal trajectories (including $r$).

    Numerical results for Case 1: $J=327.15,\;\;\; t_1 = 6.4, \;\;\; t_2 = 12.07,$

    $ s(T)=0.095341,e(T)=0.00051104,i(T)=0.0020380,ps(0)=126.5,pe(0)=2253,pi(0)=3219.
    $

    Case 2. The results of the simulations are shown in figures 6 and 7. In figure 6 the optimal control, $u^*$, and the switching function, $\phi$, are presented. As expected, $u^*=1$ and $u^*=0$ when, respectively, $\phi(t)>0$ and $\phi<0$. The optimal trajectories for the state are presented in figure 7.

    Figure 6. Case 2: Computed optimal control $u^*$ plotted together with the scaled switching function $\phi$. During the last seventeen years $\phi(t)<0$.
    Figure 7. Case 2: optimal trajectories.

    Numerical results for case 2: $J=10.181,\;\;\; t_1 = 2.71,$

    $ s(T)=0.16598,e(T)=0.0033060,i(T)=0.0079433,ps(0)=377.0,pe(0)=5137,pi(0)=7081.
    $

    When we go from case 1 to case 2, the optimal control goes from singular to bang-bang. This is because when we decrease the value of $\rho$, the weight of the control in the cost increases.

    Case 3. While keeping $\rho=500$, we now consider that only $20\%$ of the susceptible people are eligible to be vaccinated, i.e., $\bar{u}=0.2$. Results of the simulations are illustrated in figures 8 and 9. In Fig. 8 the optimal vaccinate rate, $u^*$, and the switching function, $\phi$, are presented. As expected, $u^*(t)=\bar u=0.2$ and $u^*=0$ when, respectively, $\phi>0$ and $\phi<0$. The trajectories for the state are presented in Fig. 9. The profile of the optimal control is bang-bang. The control becomes equal to zero at instant $t_1 = 16.67$.

    Figure 8. Case 3: Computed optimal control $u^*$ plotted together with the scaled switching function $\phi$. During the first sixteen years $\phi(t)>0$ and during the last three years $\phi(t)<0$.
    Figure 9. Case 3: Optimal trajectories.

    Numerical results for case 3: $J=806.12, \;\;\; t_1 = 16.67,$

    $ s(T)=0.071623,e(T)=0.0031999,i(T)=0.015275,ps(0)=1025,pe(0)=4692,pi(0)=6872.
    $

    6.1. Approximation for optimal control

    If the control is bang-bang as in case 2 and 3 second order sufficient conditions may be checked numerically as described in [15] and [16]. Here we refrain from engaging in such discussion to keep the exposition short. Here we compute numerically the switching times using the so called induced optimization problem as in [15]. Recall that the switching times are the points $t_{s1}$ at which the optimal control changes from one bound to another.

    Implementing the induced optimization problem with AMPL for case 2, with $\rho=10$ and $\bar{u}=1$ and denoting by $t_{s1}$ and $J_s$ the computed switching time and cost, we get $t_{s1}=t_1=2.71$ and $J_s=10.183$ which in contrast with $J=10.181$ is a good approximation.

    For case 3, with $\rho=500$ and $\bar{u}=0.2$, we have $t_{s1}=16.63<t_1=16-67$ while we get get a match for the cost $J_s=J=806.12$.

    We now turn to case 1 where the computed control $u^*$ is of the form of Bang-Singular-Bang. As discussed in [16], singular controls may be hard to implemented in practice. To remedy this, [16] proposes to approximate the singular control by a constant value $ \tilde{u}$. Here we do as in [16] to calculate the switching times defining the singular interval $t_{s1}$ and $t_{s2}$, the value $0\leq \tilde{u} \leq 1$ and the corresponing cost for case 1 where $\rho=500$ and $\bar{u}=1$. Using the arc parametrization method described in [15], now implemented in AMPL code, we obtain $t_{s1}=7$, $t_{s2}=11.5$, $\tilde{u} = 0.55$ with cost $J_s = 326.12$ a value very close to the previous $J = 327.15$. Figure 10 a comparison between $u^*$ and $u_{apr}$ is shown.

    Figure 10. Optimal vaccinated rate, $u^*$, in red. Approximate control $u_{apr}$, in blue dash. $\rho=500$ and $u \in [0,1]$.

    7. Conclusion

    We studied the optimal control of an epidemiological normalized SEIR model using a $L^1$-type objectives. We extracted information about the optimal solution from the Maximum Principle. In particular, we determined a closed form for the singular controls. Numerical NP solvers were applied to the discretized problem enabling us to compute optimal control solutions that match the necessary conditions, in particular, the switching conditions and forms for the singular controls.

    Moreover, we confronted this problem with the one previously studied in [16] where the so called classical SEIR model is used. The normalized model may cover in one single problem populations of different size and it is defined with what may be seen as a more realistic cost. Because of the use of normalized model, the solution of $(P_n)$ is dictated by the distribution of the population into the three different compartments and the disease characteristics. On the other hand, the normalized model has the disadvantage of not allowing the analysis of certain real situations that cannot be translated by percentages, such as when there is a limited stock of vaccine at a non-constant population. Our discussion of these two problems highlights their differences and the need for a criterion choice of cost, a challenging and relevant subject in optimal control for biomathematics problems.


    8. Acknowledgments

    The authors would like to thank Prof. Helmut Maurer for numerous and enlightening discussions on this topic as well as his help in writing up AMPL codes for the problems reported here. Thanks are due to the anonymous referees whose many comments and suggestions greatly improved this paper.

    The financial support of FEDER funds through COMPETE and Portuguese funds through the Portuguese Foundation for Science and Technology (FCT), within the FCT project PTDC/EEI-AUT/1450/2012—FCOMP-01-0124-FEDER-028894, PTDC/EEI-AUT/2933/2014, TOCCATTA -funded by FEDER funds through COMPETE2020 -POCI and FCT as well as POCI-01-0145-FEDER-006933 -SYSTEC -funded by FEDER funds through COMPETE2020 – Programa Operacional Competitividade e Internacionalização (POCI) – and by national funds through FCT -Fundação para a Ciência e a Tecnologia, are gratefully acknowledged.


    [1] Fosgerau K, Hoffmann T (2015) Peptide therapeutics: current status and future directions. Drug Discov Today 20: 122-128. doi: 10.1016/j.drudis.2014.10.003
    [2] Leader B, Baca QJ, Golan DE (2008) Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov 7: 21-39. doi: 10.1038/nrd2399
    [3] Craik DJ, Fairlie DP, Liras S, et al. (2013) The future of peptide-based drugs. Chem Biol Drug Des 81: 136-147. doi: 10.1111/cbdd.12055
    [4] Bruno BJ, Miller GD, Lim CS (2013) Basics and recent advances in peptide and protein drug delivery. Ther Deliv 4: 1443-1467. doi: 10.4155/tde.13.104
    [5] Ratnaparkhi MP, Chaudhari SP, Pandya VA (2011) Peptides and proteins in pharmaceuticals. Int J Curr Pharm Res 3 (2): 1-9.
    [6] Mullard A (2011) 2010 FDA Approvals. Nat Rev Drug Discov 10: 82-85. doi: 10.1038/nrd3370
    [7] Kneller R (2010) The importance of new companies for drug discovery: Origins of a decade of new drugs. Nat Rev Drug Discov 9: 867-882. doi: 10.1038/nrd3251
    [8] Uhlig T, Kyprianou TD, Martinelli FG, et al. (2014) The emergence of peptides in the pharmaceutical business: From exploration to exploitation. EuPA Open Proteom 4: 58-69. doi: 10.1016/j.euprot.2014.05.003
    [9] Frokjaer S, Otzen DE (2005) Protein drug stability: a formulation challenge. Nat Rev Drug Discov 4: 298-306. doi: 10.1038/nrd1695
    [10] van de Weert M, Randolph TW (2012) Physical instability of peptides and pProteins, In: Hovgaard L, Frokjaer S, Van De Weert M, Pharmaceutical Formulation Development of Peptides and Proteins, 2 Eds. , Florida: CRC Press, 107-129.
    [11] Rathore N, Rajan RS (2008) Current perspectives on stability of protein drug products during formulation, fill and finish operations. Biotechnol Prog 24: 504-514. doi: 10.1021/bp070462h
    [12] Taverna DM, Goldstein RA (2002) Why are proteins marginally stable? Proteins 46: 105-109. doi: 10.1002/prot.10016
    [13] Williams PD, Pollock DD, Goldstein RA (2006) Functionality and the evolution of marginal stability in proteins: Inferences from lattice simulations. Evol Bioinform Online 2: 91-101.
    [14] Chang BS, Yeung B (2010) Physical stability of protein pharmaceuticals, In: Jameel F, Hershenson S, Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals, New Jersey: John Wiley & Sons Inc, 69-104.
    [15] Lai MC, Topp EM (1999) Solid-state chemical stability of proteins and peptides. J Pharm Sci 88: 489-500. doi: 10.1021/js980374e
    [16] Chaudhuri R, Cheng Y, Middaugh CR, et al. (2014) High-throughput biophysical analysis of protein therapeutics to examine interrelationships between aggregate formation and conformational stability. AAPS J 16: 48-64. doi: 10.1208/s12248-013-9539-6
    [17] Jacob S, Shirwaikar A, Srinivasan K, et al. (2006) Stability of proteins in aqueous solution and solid state. Indian J Pharm Sci 68: 154-163.
    [18] Manning MC, Chou DK, Murphy BM, et al. (2010) Stability of protein pharmaceuticals: an update. Pharm Res 27: 544-575. doi: 10.1007/s11095-009-0045-6
    [19] Carpenter JF, Manning MC (2002) Rational Design of Stable Protein Formulations: Theory and Practice, New York: Kluwert Academic /Plenum Publishers.
    [20] Pace CN, Grimsley GR, Scholtz JM, et al. (2014) Protein stability. In: eLS. John Wiley & Sons Ltd, Chichester. Available from: http://onlinelibrary. wiley. com/doi/10. 1002/9780470015902. a0003002. pub3/otherversions
    [21] Banga AK (2015) Therapeutic Peptides and Proteins: Formulation, Processing, and Delivery Systems, 3 Eds. , Florida: CRC Press.
    [22] Ohtake S, Wang W (2013) Protein and peptide formulation development. Pharmaceutical Sciences Encyclopedia 11: 1-44.
    [23] Krishnamurthy R, Manning MC (2002) The stability factor: importance in formulation development. Curr Pharm Biotechnol 3: 361-371. doi: 10.2174/1389201023378229
    [24] Cicerone MT, Pikal MJ, Qian KK (2015) Stabilization of proteins in solid form. Adv Drug Deliv Rev doi: 10. 1016/j. addr. 2015. 05. 006.
    [25] Murphy KP (2001) Protein structure, stability, and folding, Series: Methods in Molecular Biology, Vol. 168, New Jersey: Humana Press.
    [26] Scheeff ED, Fink JL (2003) Fundamentals of protein structure. Methods Biochem Anal 44: 15-39.
    [27] Adler MJ, Jamieson AG, Hamilton AD (2011) Hydrogen-bonded synthetic mimics of protein secondary structure as disruptors of protein-protein interactions. Curr Top Microbiol Immunol 348: 1-23.
    [28] Kwok SC, Mant CT, Hodges RS (2002) Importance of secondary structural specificity determinants in protein folding: insertion of a native beta-sheet sequence into an alpha-helical coiled-coil. Protein Sci 11: 1519-1531.
    [29] Jorgensen L, Hostrup S, Moeller EH, et al. (2009) Recent trends in stabilizing peptides and proteins in pharmaceutical formulation - considerations in the choice of excipients. Expert Opin Drug Deliv 6: 1219-1230. doi: 10.1517/17425240903199143
    [30] Hirsch PF, Baruch H (2003) Is calcitonin an important physiological substance? Endocrine 21: 201-208. doi: 10.1385/ENDO:21:3:201
    [31] Huang CL, Sun L, Moonga BS, et al. (2006) Molecular physiology and pharmacology of calcitonin. Cell Mol Biol 52: 33-43.
    [32] Väänänen K (2005) Mechanism of osteoclast mediated bone resorption--rationale for the design of new therapeutics. Adv Drug Deliv Rev 57: 959-971. doi: 10.1016/j.addr.2004.12.018
    [33] Davey RA, Findlay DM (2013) Calcitonin: physiology or fantasy? J Bone Miner Res 28: 973-979. doi: 10.1002/jbmr.1869
    [34] Felsenfeld AJ, Levine BS (2015) Calcitonin, the forgotten hormone: does it deserve to be forgotten? Clin Kidney J 8: 180-187. doi: 10.1093/ckj/sfv011
    [35] Pondel M (2000) Calcitonin and calcitonin receptors: bone and beyond. Int J Exp Pathol 81: 405-422.
    [36] Endres DB, Rude RK (1999) Mineral and bone metabolism, In: Burtis CA, Ashwood ER Author, Textbook of Clinical Chemistry, 3 Eds. , Pennsylvania: W B Saunders Company, 1395-1457
    [37] Ramasamy I (2006) Recent advances in physiological calcium homeostasis. Clin Chem Lab Med 44: 237-273.
    [38] Chesnut CH 3rd, Azria M, Silverman S, et al. (2008) Salmon calcitonin: a review of current and future therapeutic indications. Osteoporos Int 19: 479-491. doi: 10.1007/s00198-007-0490-1
    [39] Chakraborty C, Nandi S, Sinha S (2004) Overexpression, purification and characterization of recombinant salmon calcitonin, a therapeutic protein, in Streptomyces avermitilis. Protein Pept Lett 11: 165-173. doi: 10.2174/0929866043478266
    [40] O'Connell MB (2006) Prescription drug therapies for prevention and treatment of postmenopausal osteoporosis. J Manag Care Pharm 12(6 Suppl A): S10-9, quiz S26-8.
    [41] Sexton PM, Findlay DM, Martin TJ (1999) Calcitonin. Curr Med Chem 6: 1067-1093.
    [42] Windich V, De Luccia F, Herman F, et al. (1997) Degradation pathways of salmon calcitonin in aqueous solution. J Pharm Sci 86: 359-364. doi: 10.1021/js9602305
    [43] Torres-Lugo M, Peppas NA (2000) Transmucosal delivery systems for calcitonin: a review. Biomaterials 21: 1191-1196. doi: 10.1016/S0142-9612(00)00011-9
    [44] Azria M (2003) Osteoporosis management in day-to-day practice. The role of calcitonin. J Musculoskelet Neuronal Interact 3: 210-213.
    [45] Karsdal MA, Henriksen K, Arnold M , et al. (2008) Calcitonin: a drug of the past or for the future? Physiologic inhibition of bone resorption while sustaining osteoclast numbers improves bone quality. BioDrugs 22: 137-144.
    [46] Azria M, Copp DH, Zanelli JM (1995) 25 years of salmon-calcitonin—from synthesis to therapeutic use. Calcif Tissue Int 57: 405-408. doi: 10.1007/BF00301940
    [47] D'Hondt M, Van Dorpe S, Mehuys E, et al. (2010) Quality analysis of salmon calcitonin in a polymeric bioadhesive pharmaceutical formulation: sample preparation optimization by DOE. J Pharm Biomed Anal 53: 939-945. doi: 10.1016/j.jpba.2010.06.028
    [48] Hong B, Wu B, Li Y (2003) Production of C-terminal amidated recombinant salmon calcitonin in Streptomyces lividans. Appl Biochem Biotechnol 110: 113-123. doi: 10.1385/ABAB:110:2:113
    [49] Andreassen KV, Hjuler ST, Furness SG, et al. (2014) Prolonged calcitonin receptor signaling by salmon, but not human calcitonin, reveals ligand bias. PLoS One 9: e92042. doi: 10.1371/journal.pone.0092042
    [50] Stevenson JC, Evans IM (1981) Pharmacology and therapeutic use of calcitonin. Drugs 21: 257-272. doi: 10.2165/00003495-198121040-00002
    [51] Renukuntla J, Vadlapudi AD, Patel A, et al. (2013) Approaches for enhancing oral bioavailability of peptides and proteins. Int J Pharm 447: 75-93. doi: 10.1016/j.ijpharm.2013.02.030
    [52] Hoyer H, Perera G, Bernkop-Schnürch A (2010) Noninvasive delivery systems for peptides and proteins in osteoporosis therapy: a retroperspective. Drug Dev Ind Pharm 36: 31-44. doi: 10.3109/03639040903059342
    [53] Satoh T, Yoshida G, Orito Y, et al. (1998) Drug delivery system for the treatment of osteoporosis. Nihon Rinsho 56: 742-747.
    [54] Sinsuebpol C, Chatchawalsaisin J, Kulvanich P (2013) Preparation and in vivo absorption evaluation of spray dried powders containing salmon calcitonin loaded chitosan nanoparticles for pulmonary delivery. Drug Des Devel Ther 7: 861-873.
    [55] Tas C, Mansoor S, Kalluri H, et al. (2012) Delivery of salmon calcitonin using a microneedle patch. Int J Pharm 423: 257-263. doi: 10.1016/j.ijpharm.2011.11.046
    [56] Cholewinsky M, Luckel B, Horn H (1996) Degradation pathways, analytical characterization and formulation strategies of a peptide and a protein Calcitonin and human growth hormone in comparison. Pharm Acta Helv 71: 405-419. doi: 10.1016/S0031-6865(96)00049-0
    [57] Uda K, Kobayashi Y, Hisada T, et al. (1999) Stable human calcitonin analogues with high potency on bone together with reduced anorectic and renal actions. Biol Pharm Bull 22: 244-252. doi: 10.1248/bpb.22.244
    [58] Cudd A, Arvinte T, Das RE, et al. (1995) Enhanced potency of human calcitonin when fibrillation is avoided. J Pharm Sci 84: 717-719. doi: 10.1002/jps.2600840610
    [59] Wang W, Roberts CJ (2010) Aggregation of Therapeutic Proteins, 1 Eds. , New Jersey: John Wiley & Sons Inc.
    [60] den Engelsman J, Garidel P, Smulders R, et al. (2011) Strategies for the assessment of protein aggregates in pharmaceutical biotech product development. Pharm Res 28: 920-933. doi: 10.1007/s11095-010-0297-1
    [61] Bryan J (2014) Protein aggregation: formulating a problem. Pharm J 293: 7826.
    [62] Mahler HC, Friess W, Grauschopf U, et al. (2009) Protein aggregation: pathways, induction factors, and analysis. J Pharm Sci 98: 2909-2934. doi: 10.1002/jps.21566
    [63] Brange J, Andersen L, Laursen ED, et al. (1997) Toward understanding insulin fibrillation. J Pharm Sci 86: 517-525. doi: 10.1021/js960297s
    [64] Shire SJ, Shahrokh Z, Liu J (2004) Challenges in the development of high protein concentration formulations. J Pharm Sci 93: 1390-1402. doi: 10.1002/jps.20079
    [65] Thirumangalathu R, Krishnan S, Brems DN, et al. (2006) Effects of pH, temperature, and sucrose on benzyl alcohol-induced aggregation of recombinant human granulocyte colony stimulating factor. J Pharm Sci 95: 1480-1497. doi: 10.1002/jps.20619
    [66] Wang W, Wang YJ, Wang DQ (2008) Dual effects of Tween 80 on protein stability. Int J Pharm 347: 31-38. doi: 10.1016/j.ijpharm.2007.06.042
    [67] Carpenter JF, Pikal MJ, Chang BS, et al. (1997) Rational design of stable lyophilized protein formulations: Some practical advice. Pharm Res 14: 969-975. doi: 10.1023/A:1012180707283
    [68] Chi EY, Weickmann J, Carpenter JF, et al. (2005) Heterogeneous nucleation-controlled particulate formation of recombinant human platelet-activating factor acetylhydrolase in pharmaceutical formulation. J Pharm Sci 94: 256-274. doi: 10.1002/jps.20237
    [69] KatakamM, Bell LN, Banga AK (1995) Effect of surfactants on the physical stability of recombinant human growth hormone. J Pharm Sci 84: 713-716. doi: 10.1002/jps.2600840609
    [70] Taylor JW, Jin QK, Sbacchi M, et al. (2002) Side-chain lactam-bridge conformational constraints differentiate the activities of salmon and human calcitonins and reveal a new design concept for potent calcitonin analogues. J Med Chem 45: 1108-1121. doi: 10.1021/jm010474o
    [71] Karsdal MA, Henriksen K, Arnold M, et al. (2008) Calcitonin: a drug of the past or for the future? Physiologic inhibition of bone resorption while sustaining osteoclast numbers improves bone quality. BioDrugs 22: 137-144.
    [72] Kapurniotu A, Taylor JW (1995) Structural and conformational requirements for human calcitonin activity: Design, synthesis, and study of lactam-bridged Analogues. J Med Chem 3: 836-847.
    [73] Cholewinski M, Lückel B, Horn H. (1996) Degradation pathways, analytical characterization and formulation strategies of a peptide and a protein calcitonine and human growth hormone in comparison. Pharm Acta Helv 71: 405-419.
    [74] Wang W (1999) Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm 185: 129-188.
    [75] Wang W (2000) Lyophilization and development of solid protein pharmaceuticals. Int J Pharm 203: 1-60.
    [76] Rathore N, Rajan RS (2008) Current perspectives on stability of protein drug products during formulation, fill and finish operations. Biotechnol Prog 24: 504-514. doi: 10.1021/bp070462h
    [77] Krishnamurthy R, Manning MC (2002) The stability factor: importance in formulation development. Curr Pharm Biotechnol 3: 361-371. doi: 10.2174/1389201023378229
    [78] Chang SL, Hofmann GA, Zhang L, et al. (2003) Stability of a transdermal salmon calcitonin formulation. Drug Deliv 10: 41-45. doi: 10.1080/713840326
    [79] Bauer HH, Aebi U, Häner M, et al. (1995) Architecture and polymorphism of fibrillar supramolecular assemblies produced by in vitro aggregation of human calcitonin. J Struct Biol 115: 1-15. doi: 10.1006/jsbi.1995.1024
    [80] Avidan-Shpalter C, Gazit E (2006) The early stages of amyloid formation: biophysical and structural characterization of human calcitonin pre-fibrillar assemblies. Amyloid 13: 216-225. doi: 10.1080/13506120600960643
    [81] Diociaiuti M, Gaudiano MC, Malchiodi-Albedi F (2011) The slowly aggregating salmon Calcitonin: a useful tool for the study of the amyloid oligomers structure and activity. Int J Mol Sci 12: 9277-9295. doi: 10.3390/ijms12129277
    [82] Seyferth S, Lee G (2003) Structural studies of EDTA-induced fibrillation of salmon calcitonin. Pharm Res 20: 73-80. doi: 10.1023/A:1022250809235
    [83] Nakamuta H, Orlowski RC, Epand RM (1990) Evidence for calcitonin receptor heterogenecity: binding studies with non-helical analogs. Endocrinology 127: 163-169. doi: 10.1210/endo-127-1-163
    [84] Siligardi G, Samori B, Melandri S, et al. (1994) Correlations between biological activities and conformation properties for human, salmon, eel, porcine calcitonins and Elcatonin elucidated by CD spectroscopy. Eur J Biochem 221: 1117-1125. doi: 10.1111/j.1432-1033.1994.tb18832.x
    [85] Moriarty DF, Vagts S, Raleigh DP (1998) A role for the C-terminus of calcitonin in aggregation and gel formation: a comparative study of C-terminal Fragments of human and salmon calcitonin. Biochem Biophys Res Commun 245: 344-348. doi: 10.1006/bbrc.1998.8425
    [86] van Dijkhuizen-Radersma R, Nicolas HM, van de Weert M, et al. (2002) Stability aspects of salmon calcitonin entrapped in poly(ether-ester) sustained release systems. Int J Pharm 248: 229-237. doi: 10.1016/S0378-5173(02)00458-1
    [87] Tang Y, Singh J (2010) Thermosensitive drug delivery system of salmon calcitonin: in vitro release, in vivo absorption, bioactivity and therapeutic efficacies. Pharm Res 27: 272-284. doi: 10.1007/s11095-009-0015-z
    [88] Windisch V, Deluccia F, Duhau L, et al. (1997) Degradation pathways of salmon calcitonin in aqueous solution. J Pharm Sci 86: 359-364. doi: 10.1021/js9602305
    [89] Lucke A, Kiermaier J, Gopferich A (2002) Peptide acylation by poly(α-hydroxy esters). Pharm Res 19: 175-181. doi: 10.1023/A:1014272816454
    [90] Montgomerie S, Sundararaj S, Gallin WJ, et al. (2006) Improving the accuracy of protein secondary structure prediction using structural alignment. BMC Bioinformatics 7: 301. doi: 10.1186/1471-2105-7-301
    [91] Rost B (2001) Review: protein secondary structure prediction continues to rise. J Struct Biol 134: 204-218.
    [92] Pirovano W, Heringa J (2010) Protein secondary structure prediction. Methods Mol Biol 609: 327-348. doi: 10.1007/978-1-60327-241-4_19
    [93] Kwok SC, Mant CT, Hodges RS (2002) Importance of secondary structural specificity determinants in protein folding: insertion of a native beta-sheet sequence into an alpha-helical coiled-coil. Protein Sci 11: 1519-1531. doi: 10.1110/ps.4170102
    [94] Ji YY, Li YQ (2010) The role of secondary structure in protein structure selection. Eur Phys J E Soft Matter 32: 103-107. doi: 10.1140/epje/i2010-10591-5
    [95] Haris PI, Chapman D (1995) The conformational analysis of peptides using Fourier transform IR spectroscopy. Biopolymers 37: 251-263. doi: 10.1002/bip.360370404
    [96] Manning MC (2005) Use of infrared spectroscopy to monitor protein structure and stability. Expert Rev Proteomics 2: 731-743. doi: 10.1586/14789450.2.5.731
    [97] Kong J, Yu S (2007) Fourier transform infrared spectroscopic analysis of protein secondary structures. Acta Biochim Biophys Sinica 39: 549-559
    [98] Carpenter JF, Chang BS, Garzon-Rodriguez W, et al. (2002) Rational design of stable lyophilized protein formulations: Theory and practice. Pharm Biotechnol 13: 109-133. doi: 10.1007/978-1-4615-0557-0_5
    [99] Chang LL, Pikal MJ (2009) Mechanisms of protein stabilization in the solid state. J Pharm Sci 98: 2886-2908. doi: 10.1002/jps.21825
    [100] Wang W (2000) Lyophilization and development of solid protein pharmaceuticals. Int J Pharm 203: 1-60. doi: 10.1016/S0378-5173(00)00423-3
    [101] Maa Y-F, Prestrelski SJ (2000) Biopharmaceutical powders: Particle formation and formulation considerations. Curr Pharm Biotechnol 1: 283-302. doi: 10.2174/1389201003378898
    [102] Abdul-Fattah AM, Kalonia DS, Pikal MJ (2007) The challenge of drying method selection for protein pharmaceuticals: Product quality implications. J Pharm Sci 96: 1886-1916. doi: 10.1002/jps.20842
    [103] Abdul-Fattah AM, Truong-Le V, Yee L, et al. (2007) Drying induced variations in physico-chemical properties of amorphous pharmaceuticals and their impact on stability (I): Stability of a monoclonal antibody. J Pharm Sci 96: 1983-2008. doi: 10.1002/jps.20859
    [104] Klibanov AM, Schefiliti JA (2004) On the relationship between conformation and stability in solid pharmaceutical protein formulations. Biotechnol Lett 26: 1103-1106. doi: 10.1023/B:BILE.0000035520.47933.a6
    [105] Angkawinitwong U, Sharma G, Khaw PT, et al. (2015) Solid-state protein formulations. Ther Deliv 6: 59-82. doi: 10.4155/tde.14.98
    [106] Lee TH, Cheng WT, Lin SY (2010) Thermal stability and conformational structure of salmon calcitonin in the solid and liquid states. Biopolymers 93: 200-207. doi: 10.1002/bip.21323
    [107] Stevenson CL, Tan MM (2000) Solution stability of salmon calcitonin at high concentration for delivery in an implantable system. J Pept Res 55: 129-139. doi: 10.1034/j.1399-3011.2000.00160.x
    [108] Dong A, Huang P, Caughey WS (1990) Protein secondary structures in water from second-derivative amide I infrared spectra. Biochemistry 29: 3303-3308. doi: 10.1021/bi00465a022
    [109] Kanari K, Nosaka A (1995) Study of human calcitonin fibrillation by proton nuclear magnetic resonance spectroscopy. Biochemistry 34: 12138-12143.
    [110] Arvinte T, Drake A (1993) Comparative study of human and salmon calcitonin secondary structure in solutions with low dielectric constants. J Biol Chem 268: 6408-6414.
    [111] Lee SL, Yu LX, Cai B, et al. (2011) Scientific considerations for generic synthetic salmon calcitonin nasal spray products. AAPS J 13: 14-19. doi: 10.1208/s12248-010-9242-9
    [112] Binkley N, Bone H, Gilligan JP, et al. (2014) Efficacy and safety of oral recombinant calcitonin tablets in postmenopausal women with low bone mass and increased fracture risk: a randomized, placebo-controlled trial. Osteoporos Int 25: 2649-2656. doi: 10.1007/s00198-014-2796-0
    [113] Murphy LR, Matubayasi N, Payne VA, et al. (1998) Protein hydration and unfolding-insights from experimental partial specific volumes and unfolded protein models. Fold Des 3: 105-118. doi: 10.1016/S1359-0278(98)00016-9
    [114] Schiffer CA, Dötsch V (1996) The role of protein-solvent interactions in protein unfolding. Curr Opin Biotechnol 7: 428-432. doi: 10.1016/S0958-1669(96)80119-4
    [115] Lee JC (2000) Biopharmaceutical formulation. Curr Opin Biotechnol 11: 81-84. doi: 10.1016/S0958-1669(99)00058-0
    [116] Canchi DR, García AE (2013) Cosolvent effects on protein stability. Annu Rev Phys Chem 64: 273-293. doi: 10.1146/annurev-physchem-040412-110156
    [117] England JL, Haran G (2011) Role of solvation effects in protein denaturation: from thermodynamics to single molecules and back. Annu Rev Phys Chem 62: 257-277. doi: 10.1146/annurev-physchem-032210-103531
    [118] Lee TH, Lin SY (2011) Pluronic F68 enhanced the conformational stability of salmon calcitonin in both aqueous solution and lyophilized solid form. Biopolymers 95: 785-791.
    [119] Lee TH, Lin SY (2011) Additives affecting thermal stability of salmon calcitonin in aqueous solution and structural similarity in lyophilized solid form. Process Biochem 46: 2163-2169. doi: 10.1016/j.procbio.2011.08.017
    [120] Andreotti G, Méndez BL, Amodeo P, et al. (2006) Structural determinants of salmon calcitonin bioactivity: the role of the Leu-based amphipathic alpha-helix. J Biol Chem 281: 24193-24203. doi: 10.1074/jbc.M603528200
    [121] Carpenter JF, Prestrelski SJ, Dong A (1998) Application of infrared spectroscopy to development of stable lyophilized protein formulations. Eur J Pharm Biopharm 45: 231-238. doi: 10.1016/S0939-6411(98)00005-8
    [122] Haris PI, Chapman D (1994) Analysis of polypeptide and protein structures using Fourier transform infrared spectroscopy. Methods Mol Biol 22: 183-202.
    [123] Pedone E, Bartolucci S, Rossi M, et al. (2003) Structural and thermal stability analysis of Escherichia coli and Alicyclobacillus acidocaldarius thioredoxin revealed a molten globule-like state in thermal denaturation pathway of the proteins: an infrared spectroscopic study. Biochem J 373: 875-883. doi: 10.1042/bj20021747
    [124] Cook TJ, Shenoy SS (2002) Stability of calcitonin salmon in nasal spray at elevated temperatures. Am J Health Syst Pharm 59: 713-715.
    [125] Lee KC, Lee YJ, Song HM, et al. (1992) Degradation of synthetic salmon calcitonin in aqueous solution. Pharm Res 9: 1521-1523. doi: 10.1023/A:1015839719618
    [126] Windisch V, DeLuccia F, Duhau L, et al. (1997) Degradation pathways of salmon calcitonin in aqueous solution. J Pharm Sci 86: 359-364. doi: 10.1021/js9602305
    [127] Kamihira M, Naito A, Tuzi S, et al. (2000) Conformational transitions and fibrillation mechanism of human calcitonin as studied by high-resolution solid-state 13C NMR. Protein Sci 9: 867-877. doi: 10.1110/ps.9.5.867
    [128] Andreotti G, Motta A (2004) Modulating calcitonin fibrillogenesis: an antiparallel alpha-helical dimer inhibits fibrillation of salmon calcitonin. J Biol Chem 279: 6364-6370.
    [129] Gaudiano MC, Colone M, Bombelli C, et al. (2005) Early stages of salmon calcitonin aggregation: effect induced by ageing and oxidation processes in water and in the presence of model membranes. Biochim Biophys Acta 1750: 134-145. doi: 10.1016/j.bbapap.2005.04.008
    [130] Diociaiuti M, Macchia G, Paradisi S, et al. (2014) Native metastable prefibrillar oligomers are the most neurotoxic species among amyloid aggregates. Biochim Biophys Acta 1842: 1622-1629. doi: 10.1016/j.bbadis.2014.06.006
    [131] Gilchrist PJ, Bradshow JP (1993) Amyloid formation by salmon calcitonin. Biochim Biophys Acta 1182: 111-114. doi: 10.1016/0925-4439(93)90160-3
    [132] Arvinte T, Cudd A, Drake AF (1993) The structure and mechanism of formation of human calcitonin fibrils. J Biol Chem 268: 6415-6422.
    [133] Rastogi N, Mitra K, Kumar D, et al. (2012) Metal ions as cofactors for aggregation of therapeutic peptide salmon calcitonin. Inorg Chem 51: 5642-5650. doi: 10.1021/ic202604v
    [134] Diociaiuti M, Macchia G, Paradisi S, et al. (2014) Native metastable prefibrillar oligomers are the most neurotoxic species among amyloid aggregates. Biochim Biophys Acta 1842: 1622-1629. doi: 10.1016/j.bbadis.2014.06.006
    [135] Rawat A, Kumar D (2013) NMR investigations of structural and dynamics features of natively unstructured drug peptide-salmon calcitonin: implication to rational design of potent sCT analogs. J Pept Sci 19: 33-45. doi: 10.1002/psc.2471
    [136] Allison SD, Randolph TW, Manning MC, et al. (1998) Effects of drying methods and additives on structure and function of actin: mechanisms of dehydration-induced damage and its inhibition. Arch Biochem Biophys 358: 171-181. doi: 10.1006/abbi.1998.0832
    [137] Bhatnagar BS, Bogner RH, Pikal MJ (2007) Protein stability during freezing: separation of stresses and mechanisms of protein stabilization. Pharm Dev Technol 12: 505-523.
    [138] Jain NK, Roy I (2009) Effect of trehalose on protein structure. Protein Sci 18: 24-36.
    [139] Capelle MA, Gurny R, Arvinte T (2007) High throughput screening of protein formulation stability: practical considerations. Eur J Pharm Biopharm 65: 131-148. doi: 10.1016/j.ejpb.2006.09.009
    [140] Kamerzell TJ, Esfandiary R, Joshi SB, et al. (2011) Protein-excipient interactions: mechanisms and biophysical characterization applied to protein formulation development. Adv Drug Deliv Rev 63: 1118-1159. doi: 10.1016/j.addr.2011.07.006
    [141] Ohtake S, Kita Y, Arakawa T (2011) Interactions of formulation excipients with proteins in solution and in the dried state. Adv Drug Deliv Rev 63: 1053-1073. doi: 10.1016/j.addr.2011.06.011
    [142] Porfire AS, Tomuţa I, Irache JM, et al. (2009) The influence of the formulation factors on physico-chemical properties of dextran associated Gantrez an nanoparticles. Farmacia 57: 463-472.
    [143] Torres-Lugo M, Peppas NA (1999) Molecular design and in vitro studies of novel pH-sensitive hydrogels for the oral delivery of calcitonin. Macromolecules 32: 6646-6651.
    [144] Szelke H, Schübel S, Harenberg J, et al. (2010) Interaction of heparin with cationic molecular probes: probe charge is a major determinant of binding stoichiometry and affinity. Bioorg Med Chem Lett 20: 1445-1447. doi: 10.1016/j.bmcl.2009.12.105
    [145] Houska M, Brynda E (1997) Interactions of proteins with polyelectrolytes at solid/liquid interfaces: Sequential adsorption of albumin and heparin. J Colloid Interface Sci 188: 243-250. doi: 10.1006/jcis.1996.4576
    [146] Guo B, Anzai J, Osa T (1996) Adsorption behavior of serum albumin on electrode surfaces and the effects of electrode potential. Chem Pharm Bull (Tokyo) 44: 800-803. doi: 10.1248/cpb.44.800
    [147] Langer K, Balthasar S, Vogel V, et al. (2003) Optimization of the preparation process for human serum albumin (HSA) nanoparticles. Int J Pharm 257: 169-180. doi: 10.1016/S0378-5173(03)00134-0
    [148] Prestrelski SJ, Pikal KA, Arakawa T (1995) Optimization of lyophilization conditions for recombinant human interleukin-2 by dried-state conformational analysis using fourier-transform infrared spectroscopy. Pharm Res 12: 1250-1259. doi: 10.1023/A:1016296801447
    [149] van Dijkhuizen-Radersma R, Nicolas HM, van de Weert M, et al. (2002) Stability aspects of salmon calcitonin entrapped in poly(ether-ester) sustained release systems. Int J Pharm 248: 229-237. doi: 10.1016/S0378-5173(02)00458-1
    [150] Baudys M, Mix D, Kim SW (1996) Stabilization and intestinal absorption of human calcitonin. J Control Rel 39: 145-151. doi: 10.1016/0168-3659(95)00148-4
    [151] Sigurjónsdóttir JF, Loftsson T, Másson M (1999) Influence of cyclodextrins on the stability of the peptide salmon calcitonin in aqueous solution. Int J Pharm 186: 205-213. doi: 10.1016/S0378-5173(99)00183-0
    [152] Mueller C, Capelle MA, Arvinte T, et al. (2011) Noncovalent pegylation by dansyl-poly(ethylene glycol)s as a new means against aggregation of salmon calcitonin. J Pharm Sci 100: 1648-1662. doi: 10.1002/jps.22401
    [153] Mueller C, Capelle MA, Arvinte T, et al. (2011) Tryptophan-mPEGs: novel excipients that stabilize salmon calcitonin against aggregation by non-covalent PEGylation. Eur J Pharm Biopharm 79: 646-657. doi: 10.1016/j.ejpb.2011.06.003
    [154] Mueller C, Capelle MA, Seyrek E, et al. (2012) Noncovalent PEGylation: different effects of dansyl-, L-tryptophan-, phenylbutylamino-, benzyl- and cholesteryl-PEGs on the aggregation of salmon calcitonin and lysozyme. J Pharm Sci 101: 1995-2008. doi: 10.1002/jps.23110
    [155] Remmele RL, Krishnan S, Callahan WJ (2012) Development of stable lyophilized protein drug products. Curr Pharm Biotechnol 13: 471-496. doi: 10.2174/138920112799361990
    [156] Kasper JC, Friess W (2011) The freezing step in lyophilization: physico-chemical fundamentals, freezing methods and consequences on process performance and quality attributes of biopharmaceuticals. Eur J Pharm Biopharm 78: 248-263. doi: 10.1016/j.ejpb.2011.03.010
    [157] Costantino HR, Pikal MJ (2004) Lyophilization of Biopharmaceuticals. Virginia: AAPS Press.
    [158] Susi H, Byler DM (1983) Protein structure by Fourier transform infrared spectroscopy: second derivative spectra. Biochem Biophys Res Commun 115: 391-397. doi: 10.1016/0006-291X(83)91016-1
    [159] Prestrelski SJ, Tedeschi N, Arakawa T, et al. (1993) Dehydration-induced conformational transitions in proteins and their inhibition by stabilizers. Biophys J 65: 661-671. doi: 10.1016/S0006-3495(93)81120-2
    [160] Lee HE, Lee MJ, Park CR, et al. (2010) Preparation and characterization of salmon calcitonin-sodium triphosphate ionic complex for oral delivery. J Control Rel 143: 251-257. doi: 10.1016/j.jconrel.2009.12.011
    [161] Steckel H, Brandes HG (2004) A novel spray-drying technique to produce low density particles for pulmonary delivery. Int J Pharm 278: 187-195. doi: 10.1016/j.ijpharm.2004.03.010
    [162] Seville PC, Li HY, Learoyd TP (2007) Spray-dried powders for pulmonary drug delivery. Crit Rev Ther Drug Carrier Syst 24: 307-360. doi: 10.1615/CritRevTherDrugCarrierSyst.v24.i4.10
    [163] Sollohub K, Cal K (2010) Spray drying technique: II. Current applications in pharmaceutical technology. J Pharm Sci 99: 587-597.
    [164] Telko M, Hickey A (2005) Dry powder inhaler formulation. Respir Care 50: 1209-1227.
    [165] Ameri M, Maa Y (2006) Spray Drying of Biopharmaceuticals: Stability and Process Considerations. Drying Technol: A Int J 24: 763-768. doi: 10.1080/03602550600685275
    [166] Chan HK, Clark AR, Feeley JC, et al. (2004) Physical stability of salmon calcitonin spray-dried powders for inhalation. J Pharm Sci 93: 792-804. doi: 10.1002/jps.10594
    [167] Yang M, Velaga S, Yamamoto H, et al. (2007) Characterisation of salmon calcitonin in spray-dried powder for inhalation. Effect of chitosan. Int J Pharm 331: 176-181.
    [168] Sinsuebpol C, Chatchawalsaisin J, Kulvanich P (2013) Preparation and in vivo absorption evaluation of spray dried powders containing salmon calcitonin loaded chitosan nanoparticles for pulmonary delivery. Drug Des Devel Ther 7: 861-873.
    [169] Amaro MI, Tewes F, Gobbo O, et al. (2015) Formulation, stability and pharmacokinetics of sugar-based salmon calcitonin-loaded nanoporous/nanoparticulate microparticles (NPMPs) for inhalation. Int J Pharm 483: 6-18.
    [170] Lechuga-Ballesteros D, Charan C, Stults CL, et al. (2008) Trileucine improves aerosol performance and stability of spray-dried powders for inhalation. J Pharm Sci 97: 287-302. doi: 10.1002/jps.21078
    [171] Tewes F, Gobbo OL, Amaro MI, et al. (2011) Evaluation of HP βCD-PEG microparticles for salmon calcitonin administration via pulmonary delivery. Mol Pharm 8: 1887-1898. doi: 10.1021/mp200231c
    [172] Epand RM, Epand RF, Orlowski RC, et al. (1983) Amphipathic helix and its relationship to the interaction of calcitonin with phospholipids. Biochemistry 22: 5074-5084.
    [173] Epand RM, Epand RF (1986) Conformational flexibility and biological activity of salmon calcitonin. Biochemistry 25: 1964-1968.
    [174] Green FR 3rd, Lynch B, Kaiser ET (1987) Biological and physical properties of a model calcitonin containing a glutamate residue interrupting the hydrophobic face of the idealized amphiphilic alpha-helical region. Proc Natl Acad Sci U S A 84: 8340-8344. doi: 10.1073/pnas.84.23.8340
    [175] Nabuchi Y, Asoh Y, Takayama M (2004) Folding analysis of hormonal polypeptide calcitonins and the oxidized calcitonins using electrospray ionization mass spectrometry combined with H/D exchange. J Am Soc Mass Spectrom 15: 1556-1564. doi: 10.1016/j.jasms.2004.07.007
    [176] Siligardi G, Samorí B, Melandri S, et al. (1994) Correlations between biological activities and conformational properties for human, salmon, eel, porcine calcitonins and Elcatonin elucidated by CD spectroscopy. Eur J Biochem 221: 1117-1125. doi: 10.1111/j.1432-1033.1994.tb18832.x
    [177] Andreotti G, Méndez BL, Amodeo P, et al. (2006) Structural determinants of salmon calcitonin bioactivity: the role of the Leu-based amphipathic alpha-helix. J Biol Chem 281: 24193-24203. doi: 10.1074/jbc.M603528200
    [178] Stefani M (2004) Protein misfolding and aggregation: new examples in medicine and biology of the dark side of the protein world. Biochim Biophys Acta 1739: 5-25. doi: 10.1016/j.bbadis.2004.08.004
    [179] Renukuntla J, Vadlapudi AD, Patel A, et al. (2013) Approaches for enhancing oral bioavailability of peptides and proteins. Int J Pharm 447: 75-93. doi: 10.1016/j.ijpharm.2013.02.030
    [180] Choonara BF, Choonara YE, Kumar P, et al. (2014) A review of advanced oral drug delivery technologies facilitating the protection and absorption of protein and peptide molecules. Biotechnol Adv 32: 1269-1282. doi: 10.1016/j.biotechadv.2014.07.006
    [181] Smart AL, Gaisford S, Basit AW (2014) Oral peptide and protein delivery: intestinal obstacles and commercial prospects. Expert Opin Drug Deliv 11: 1323-1335. doi: 10.1517/17425247.2014.917077
    [182] Franks F, Hatley RHM, Mathias SF (1991) Materials science and the production of shelf-stable biologicals. Pharm Technol Int 3: 24-34.
    [183] Slade L, Levine H (1991) Beyond water activity: Recent advances based on an alternative approach to the assessment of food quality and safety. Crit Rev Food Sci Nutri 30: 115-360. doi: 10.1080/10408399109527543
    [184] Carpenter JF, Prestrelski SJ, Arakawa T (1993) Separation of freezing- and drying-induced denaturation of lyophilized proteins using stress-specific stabilization. I. Enzyme activity and calorimetric studies. Arch Biochem Biophys 303: 456-464.
    [185] Carpenter JF, Crowe JH (1989) An infrared spectroscopic study of the interactions of carbohydrates with dried proteins. Biochemistry 28: 3916-3922. doi: 10.1021/bi00435a044
    [186] Crowe JH, Crowe LM, Carpenter JF (1993) Preserving dry biomaterials: The water replacement hypothesis, Part 1. BioPharm 6: 28-29, 32-33.
    [187] Crowe JH, Crowe LM, Carpenter JF (1993) Preserving dry biomaterials: the water replacement hypothesis, Part 2. BioPharm 6: 40-43.
  • This article has been cited by:

    1. Asaf Khan, Gul Zaman, Optimal control strategy of SEIR endemic model with continuous age-structure in the exposed and infectious classes, 2018, 39, 01432087, 1716, 10.1002/oca.2437
    2. Hamadjam Abboubakar, Jean Claude Kamgang, Leontine Nkague Nkamba, Daniel Tieudjo, Bifurcation thresholds and optimal control in transmission dynamics of arboviral diseases, 2018, 76, 0303-6812, 379, 10.1007/s00285-017-1146-1
    3. Urszula Ledzewicz, Mahya Aghaee, Heinz Schattler, 2016, Optimal control for a SIR epidemiological model with time-varying populations, 978-1-5090-0755-4, 1268, 10.1109/CCA.2016.7587981
    4. Maria do Rosário de Pinho, Filipa Nunes Nogueira, Costs analysis for the application of optimal control to SEIR normalized models, 2018, 51, 24058963, 122, 10.1016/j.ifacol.2018.11.656
    5. Maria do Rosário de Pinho, Helmut Maurer, Hasnaa Zidani, Optimal control of normalized SIMR models with vaccination and treatment, 2018, 23, 1553-524X, 79, 10.3934/dcdsb.2018006
    6. Y.M. Rangkuti, A. Landong, Control optimal analysis of SEIR model of covid 19 spread in Indonesia, 2022, 2193, 1742-6588, 012091, 10.1088/1742-6596/2193/1/012091
    7. Hassan Tahir, Asaf Khan, Anwarud Din, Amir Khan, Gul Zaman, Optimal control strategy for an age-structured SIR endemic model, 2021, 14, 1937-1179, 2535, 10.3934/dcdss.2021054
    8. Asaf Khan, Gul Zaman, Optimal control strategies for an age‐structured SEIR epidemic model, 2022, 45, 0170-4214, 8701, 10.1002/mma.7823
    9. Saroj K Biswas, Nasir U Ahmed, Mathematical modeling and optimal intervention of COVID‐19 outbreak, 2021, 9, 2095-4689, 84, 10.15302/J-QB-020-0229
    10. Haojie Hou, Youguo Wang, Qiqing Zhai, Xianli Sun, Synergistic control of negative information diffusion in improved semi-randomized epidemic networks, 2024, 0924-090X, 10.1007/s11071-024-10817-2
  • Reader Comments
  • © 2015 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(13554) PDF downloads(2239) Cited by(2)

Article outline

Figures and Tables

Figures(11)  /  Tables(2)

Other Articles By Authors

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog